Preparation of Active Pharmaceutical Ingredients...

34
BRIAN MARQUARDT WES THOMPSON APPLIED PHYSICS LABORATORY UNIVERSITY OF WASHINGTON [email protected] Preparation of Active Pharmaceutical Ingredients (API) by Continuous Processing MEPI U.S. Food and Drug Administration

Transcript of Preparation of Active Pharmaceutical Ingredients...

Page 1: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

B R I A N M A R Q U A R D TW E S T H O M P S O NA P P L I E D P H Y S I C S L A B O R A T O R YU N I V E R S I T Y O F W A S H I N G T O Nm a r q u a r d t @ a p l . w a s h i n g t o n . e d u

Preparation of Active Pharmaceutical Ingredients

(API) by Continuous Processing

MEPIU.S. Food andDrug Administration

Page 2: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Why Use Advanced Flow Reactors?

High Throughput Experimentation For…Discovery and screeningProcess developmentProcess optimizationProcess controlProduction?

Eliminate chemical engineering production problems related to scaling up batch systems?Increase production through use of many parallel microreactors to achieve volume?

Page 3: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Challenges To Using AF Reactors

EDUCATION!!!!!!Interfacing modular unitsSampling and screeningAnalytical characterizationData handlingProcess modeling and feed back control (particularly if they are used for production)

Page 4: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Example: Esterification of Methanol

Standard Raman spectra

Acetic Acid + Methanol Methyl Acetate + H2OH+

Raman Shift (cm-1)

Inte

nsity

Acetic AcidMethanol Methyl Acetate

0

5000

10000

15000

20000

400 600 800 1000 1200 1400 1600 1800

ROI

Page 5: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

• PCA analysis of the formation of acetate monitoredby Raman spectroscopy – reaction time 1.5 hours

0 30 600

50

100

150

200

250

Rel

ativ

e In

tens

ity

90Reaction Time (min.)

15º25º35º

55º 45º65º

Batch Runs at Different Temperatures

Page 6: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Continuous Rxn. with Temp. Step

• with residence time module• flow rate: 10.56 ml/min (residence time ~ 2.5 min)

acetic acid

methyl acetate

Temp 40°C

Temp 25°C (25°C – 40°C)

• With control of flow reactor parameters and analytics, fast optimization is possible

Page 7: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

• without residence time module• flow rate: 0.89 ml/min (residence time ~ 5 min)

PCA Analysis on data after mixing:1st PCA scores Increase in reaction yield after each temperature step

Product Yield vs. Temperature

Range = 30-60°C

• 2 weeks of batch data reproduced in less than three hours by continuous flow

Page 8: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Result: Estimated Response SurfacesD

esira

bilit

y

50% Time - 50% Product• Optimum response

- H2SO4= 0.230 ml- Ratio= 1.35 Ac + 1.65 MeOH- Temp = 45ºC

temp=40.0

0 100 200 300 01

23

Ratio(x1000)

00.20.40.60.8

1

H2SO4

20% Time - 80% Product• Optimum response

-H2SO4= 0.258 ml -Ratio= 1.34 Ac+1.66 MeOH -Temp = 46ºC

temp=40.0

Ratio(X 1000)

0 100 200 300 01

23

00.20.40.60.8

1

H2SO4

80% Time - 20% Product• Optimum response

-H2SO4= 0.141 ml-Ratio= 1.45 Ac + 1.55 MeOH-Temp = 51.4ºC

temp=40.0

H2SO4 Ratio(x1000)

0 100 200 300 01

23

00.20.40.60.8

1

• continuous reactors w/analytics allow for fast optimization of design space

Page 9: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Analysis of Continuous Reactors

Problems with performing online measurementsGas formation in sample linesTemperature change before reaching analyzerPhase change between reactor and analyzerSensor placement at optimal positionAutomated flow and pressure control

Most PAT problems are due to sampling not measurement deviceNeed better systems to sample processes

Page 10: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Application of Sampling Systems To Microreactors

EXAMPLE OF BRINGING ANALYTICS TO A PROCESS AND THE CHALLENGES WITH INTEGRATING THEM

Page 11: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

What is NeSSI?• Industry-driven effort to

define and promote a new standardized alternative to sample conditioning systems for analyzers and sensors

Standard fluidic interface for modular surface-mount components

ISA SP76 Standard wiring and communications interfacesStandard platform formicro analytics

Page 12: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

What does NeSSI™ Provide

Simple “Lego-like” assemblyEasy to re-configureNo special tools or skills required

Standardized flow components“Mix-and-match” compatibility between vendorsGrowing list of components

Standardized electrical and communication (Gen II)“Plug-and-play” integration of multiple devicesSimplified interface for programmatic I/O and control

Advanced analytics (Gen III)Micro-analyzersIntegrated analysis or “smart” systems

Page 13: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

NeSSI Raman Sampling Block

• Parker Intraflow NeSSI substrate• Sample conditioning to induce backpressure to

reduce bubble formation and the heated substrate allows analysis at reactor conditions

Page 14: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Reactor Feed 1

Reactor Feed 2

Product Stream

Real-timeCalibration

waste

prod

AnalyzerSuite

Pump 1

Pump 2

NESSI AF Reactor Sampling/Calibration

• Application of sampling systems and analytics to optimize and control AF reactor

Page 15: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

FDA Collaboration: Demonstrate the Concept of QbD

- Monitoring an advanced flow reactor (AF Reactor) using NeSSi sampling systems and Raman ballprobe sampling interfaces at various reactor points.

Page 16: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

CPAC/FDA/Corning AF Reactor

Goal: to improve reaction development and optimization through the use of continuous glass flow reactors, NeSSI and analyticsFunded by the FDA to demonstrate the benefits of improved reactor design, effective sampling and online analytics to increase process understanding (QbD)Partners: FDA, Corning, CPAC, Kaiser, ParkerQbD Project began November 2008Process Reactions – June 2009

Page 17: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Corning Advanced Flow Reactor

Continuous reactions are ideal for product and process optimization/ understandingProvide predictable and reliable reaction performance, easily customizable and transferable to a production facility Application of reactor, sampling and analytics, demonstrates the physical concept of QbD Additional analytics easily coupled to reactor through NeSSI substrates

4 channel, Kaiser Optical Systems Rxn2 probes placed in reactor flow path at different points of the reaction

Page 18: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Advanced Flow Reactor Chemistry

Organic Acid Chloride Organic Carbonate + dimer

Page 19: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Raman Analysis of AF Reactor

3 4

1

2

• monitor reaction with 4 channel 785 nm Raman system• NeSSI sampling systems (1-4) equipped with Raman ballprobes• Online GC also used as post quench online analyzer (4)

Page 20: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

For each feed :

PressureMass Flow rateTemperatureDensity

Raman Spectroscopy measurements on Feeds, Pre‐quench product and Post‐quench productDensity and viscosity measurements were done for Chloroformate/Toluene and Butanediol/Pyridine

Process on line measurements

Chloroformate in Toluene

0,6

0,65

0,7

0,75

0,8

0,85

0,9

0,95

1

0 20 40 60 80

mass % 2EHCF

0,5

0,6

0,7

0,8

0,9

1

1,1

DensityViscosity (cp)

Pyridine in Butanediol

0,5

0,7

0,9

1,1

1,3

1,5

0 5 10 15 20mass % pyridine

20

30

40

50

60

70

80

Density

Viscosity (cp)

Page 21: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Advanced Flow Reactor Images

Raman Probes

Page 22: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

NeSSI Sampling and Raman Probe Images

Page 23: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

NeSSI Ballprobe - Raman/NIR/UV

Matrix Solutions: www.ballprobe.com

Page 24: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Design of Experiments Information

31 Experiments totalTemperature stepsReaction with no tolueneChanges in butanediol ratioChanges in pyridine ratioPropanediol instead of butanediolSimulated Reactor problems

Pump failureLess heat exchangePoor dilution of chloroformate

Page 25: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Product Raman Peaks of Interest

Page 26: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Standard Peaks of Interest (High cm-1)

Chloroformate

Dimer

Carbonate

Page 27: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Standard Peaks of Interest (Low cm-1)

Chloroformate

TolueneDimerCarbonateToluene

Page 28: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

C F M _ R U N 1J U N E 9 T H , 2 0 0 9

DoE Tests 0 and 3

T° Feed A Feed BMass FlowA+B

Feed C T°Total Mass Flow

Reaction Choloformiate in toluene Pyridine in butanediol Acidic solution Quench

°C g/min wt% g/min wt%

Eq Mol Pyridine

Eq Mol Butaned

iol g/min g/min wt% °C g/min

Half stoechiometry test

Test 0 60 10.0 40 10.1 8.1 0.5 5.0 20.1 20.2 10 10 40.3

TemperatureTest 1 20 8.0 40.0 16.0 8.1 1.0 9.8 24.0 20.2 10.0 10 44.2Test 2 40 8.0 40.0 16.0 8.1 1.0 9.8 24.0 20.2 10.0 10 44.2

Test 3 60 8.0 40.0 16.0 8.1 1.0 9.8 24.0 20.2 10.0 10 44.2

Propanediol instead of butanediol

Test 15 60 8.0 30.0 16.0 8.1 1.3 15.5 24.0 20.2 10.0 10 44.2Test 16 85 8.0 30.0 16.0 8.1 1.3 15.5 24.0 20.2 10.0 10 44.2

Test 17 30 8.0 30.0 16.0 8.1 1.3 15.5 24.0 20.2 10.0 10 44.2

GC Results (%)

R-OH 2EHCF R-Cl Carbonate Dimer2.16 45.84 0.32 51.42 0.591.17 0.00 0.26 96.17 2.40

Abbreviation DefinitionsR-OH 2EHCF R-Cl

Alcohol formed after quench

Residual, unreactedchloroformate

Natural degradation product of chloroformate

Page 29: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Reaction Easily Followed With Raman

Test 3 Test 0Toluene Flush

Ch. 1

Page 30: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Peaks of Interest (High cm-1)

Dimer Chloroformate

Ch. 1GC Results (%)

Test R-OH 2EHCF R-Cl Carbonate Dimer0 2.16 45.84 0.32 51.42 0.593 1.17 0.00 0.26 96.17 2.40

Page 31: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Peaks of Interest (Low cm-1)

Chloroformate

Toluene

Toluene

Ch. 1GC Results (%)

Test R-OH 2EHCF R-Cl Carbonate Dimer0 2.16 45.84 0.32 51.42 0.593 1.17 0.00 0.26 96.17 2.40

Page 32: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

PCA of fingerprint region, PC 1

Toluene peaks removed

Toluene Flush Toluene Flush

Test 0

Test 3

Scores Loadings

Page 33: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Current Status

Data collected and organized14 days in Toulouse France

Analysis startedEvaluation of modeling protocols

PCA, MCR, ALS

Calibrate to GC results (PLS)Determine better chemistry for Phase 2

More chemical change in reaction spaceImplement more sensorsAcquire reactor at CPAC

Implement Models for Process Feedback Control

Page 34: Preparation of Active Pharmaceutical Ingredients …depts.washington.edu/cpac/Activities/Meetings/documents/...Preparation of Active Pharmaceutical Ingredients (API) by Continuous

Thanks

U.S. Food and Drug AdministrationMoheb NasrChristine MooreDavid MorleyErik Henrikson

Corning GlassPhilipe CazeCeline GuermerJérémy Jorda

ParkerMike Cost

Kaiser Optical SystemsIan LewisHervé LucasBruno Lenain

CPACUniversity of WashingtonApplied Physics Lab

La Maison Européenne des Procédés Innovants (MEPI )

Annelyse Conté MEPI

U.S. Food andDrug Administration